Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer.
10.1158/1078-0432.CCR-17-2587 Muliaditan et al. Clin. Cancer Res. Cited 4 times
Muliaditan T, Opzoomer JW, Caron J, Okesola M, Kosti P, Lall S, Van Hemelrijck M, Dazzi F, Tutt A, Grigoriadis A, Gillett C, Madden SF, Burchell JM, Kordasti S, Diebold SS, Spicer J, Arnold JN
Study details